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Background: BQCA is a selective allosteric modulator of the M1 mAChR.
Results: Residues that govern BQCA activity were identified using mutagenesis and molecular modeling.
Conclusion: BQCA likely occupies a pocket overlapping prototypical mAChR modulators and gains selectivity through coop-
erativity with orthosteric ligands.
Significance: Understanding the structural basis of BQCA function can provide insight into the design of more tailored
allosteric ligands.
Benzylquinolone carboxylic acid (BQCA) is an unprece-
dented example of a selective positive allosteric modulator of
acetylcholine at the M1 muscarinic acetylcholine receptor
(mAChR). To probe the structural basis underlying its selectiv-
ity, we utilized site-directed mutagenesis, analytical modeling,
and molecular dynamics to delineate regions of the M1 mAChR
that govern modulator binding and transmission of cooperativ-
ity. We identified Tyr-852.64 in transmembrane domain 2
(TMII), Tyr-179 and Phe-182 in the second extracellular loop
(ECL2), and Glu-3977.32 and Trp-4007.35 in TMVII as residues
that contribute to the BQCAbinding pocket at theM1mAChR, as
well as to the transmission of cooperativity with the orthosteric
agonist carbachol. As such, the BQCA binding pocket partially
overlaps with the previously described “common” allosteric site
in the extracellular vestibule of the M1 mAChR, suggesting that
its high subtype selectivity derives from either additional con-
tacts outside this region or through a subtype-specific coopera-
tivitymechanism.Mutationof aminoacid residues that form the
orthosteric binding pocket caused a loss of carbachol response
that could be rescued by BQCA. Two of these residues (Leu-
1023.29 andAsp-1053.32) were also identified as indirect contrib-
utors to the binding affinity of the modulator. This new insight
into the structural basis of binding and function of BQCA can
guide the design of new allosteric ligands with tailored pharma-
cological properties.
G protein-coupled receptors (GPCRs)5 mediate a multitude
of biological functions in response to a variety of ligands,
including hormones and neurotransmitters, and play essential
roles in all physiological processes (1). As such, GPCRs are
important therapeutic targets for numerous diseases (2). Given
such importance, an understanding of the structural basis
underlying ligand binding and activation of GPCRs is essential
to design more effective therapies (3). The recent surge in high
resolution family A GPCR crystal structures (4) has provided
new insights into the structural and functional diversity of this
protein family. This knowledge, combined with information
fromcomputational, biochemical, andmutagenesis studies, has
not only mapped out the location of orthosteric binding pock-
ets but is starting to unravel the molecular changes that occur
upon receptor activation and the mechanisms by which differ-
ent ligands stabilize distinct conformational states (5, 6).
The M1 mAChR is a family A GPCR and is one of five
mAChR subtypes for which acetylcholine (ACh) is the endog-
enous orthosteric agonist. The ACh binding pocket is formed
by amino acids that are conserved across all five mAChR sub-
types and shares structural homology with other functionally
unrelated acetylcholine-binding proteins fromdifferent species
(7). Along with theM4mAChR, theM1mAChR is an attractive
therapeutic target for the treatment of diseases in which cogni-
tion is impaired, such as Alzheimer disease and schizophrenia
(8). However, because of the highly homologous ACh binding
pocket across subtypes, it has been challenging to develop drugs
that are sufficiently subtype-selective to avoid undesired activ-
ity at other mAChRs. This has spurred intensive efforts to dis-
cover allosteric ligands that act at topographically distinct
regions on these receptors (9) with more potential to confer
subtype selectivity. Despite the wealth of information obtained
from GPCR crystal structures, challenges remain in under-
standing themode of binding and action of such smallmolecule
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allostericmodulators (9).High resolution structures of familyA
GPCRs bound to allosteric modulators are only starting to be
solved (10), and even then the dynamic mechanisms contribut-
ing tomodulator binding, receptor activation, and transmission
of cooperativity between orthosteric and allosteric sites cannot
be readily captured in a single structure.
The conservedACh-binding site inmAChRs is located in the
top third of the transmembrane helical bundle of the receptor
with ACh contacting inward-facing residues in ECL2 and
TMIII–VII (7, 11). In particular, TMIII contains a number of
residues that have been implicated in both binding and activa-
tion mechanisms of the mAChRs and plays a central role as a
structural and functional hub ofmanyGPCRs (1). Accumulated
evidence also points toward the existence of a “common” allo-
steric binding pocket utilized by structurally diverse mAChR
allosteric modulators (12–14). This site is located within an
extracellular “vestibule” and includes residues from both ECL2
and the extracellular regions of TMII and -VII (12, 13). Inter-
estingly, we recently demonstrated that LY2033298, an allo-
steric modulator originally described as being a “selective” pos-
itive allosteric modulator for ACh at the M4 mAChR, can also
occupy this conserved allosteric pocket at theM2mAChR, where
it exerts cooperative behavior with alternative orthosteric ago-
nists, such as oxotremorine M, but not with ACh (14). Such
probe dependence highlights the fact that selectivity of allo-
steric agents can actually be attained through twomechanisms,
namely the differences in the allosteric site between receptor
subtypes or the differences in cooperativity upon binding to a
common allosteric site.
With regard to theM1mAChR, several selective ligands have
been discovered in the past few years (15). Among these, ben-
zylquinolone carboxylic acid (BQCA) is a novel example of a
highly selective positive allosteric modulator of ACh binding
and function at theM1mAChR, displaying very low affinity but
a remarkably high cooperativity with ACh (16–18). The
unprecedented subtype selectivity of BQCA thus suggests two
potential scenarios as follows: (i) that BQCA binds to a com-
pletely different site than other mAChR allosteric modulators
or (ii) that BQCA achieves subtype-selective cooperativity
upon interactionwith a conserved or overlapping allosteric site.
In this study, we aimed to resolve this issue by site-directed
mutagenesis of residues previously shown to be important for
orthosteric, allosteric, or bitopic (dual orthosteric-allosteric)
ligand binding at either theM1mAChRor othermAChR family
subtypes. Importantly, we also applied an analytical approach,
based on the operationalmodel of agonism (19, 20), to elucidate
the effects of the introducedmutations on ligand binding versus
signaling versus transmission of cooperativity. By doing so, we
present new evidence for differential effects of distinct receptor
regions on each of these molecular properties at the M1
mAChR.
EXPERIMENTAL PROCEDURES
Materials—Chinese hamster ovary (CHO) FlpIn cells and
Dulbecco’s modified Eagle’s medium (DMEM) were purchased
from Invitrogen. Fetal bovine serum (FBS) was purchased from
ThermoTrace (Melbourne, Australia). Hygromycin-B was pur-
chased from Roche Applied Science. [3H]Quinuclidinyl ben-
zilate ([3H]QNB; specific activity, 50 Ci/mmol), N-[3H]meth-
ylscopolamine ([3H]NMS); specific activity, 85 Ci/mmol), and
MicroScint scintillation liquid were purchased from Perkin-
Elmer Life Sciences. IP-One assay kit and reagents were pur-
chased fromCisbio (Codolet, France). All other chemicals were
purchased from Sigma. BQCA was synthesized in-house at the
Monash Institute of Pharmaceutical Sciences.
Cell Culture and Receptor Mutagenesis—Mutations of the
c-Myc-hM1 mAChR sequence were generated using the
QuikChange site-directed mutagenesis kit (Agilent Technolo-
gies, La Jolla, CA). All mutations were confirmed by DNA
sequencing (AGRF, Australia). Mutant c-Myc-hM1 mAChR
DNA constructs were transfected into FlpIn CHO cells (Invit-
rogen) and selected using 0.2 mg/ml hygromycin for stable
expression.
Whole Cell Radioligand Binding Assays—To facilitate amore
direct comparison between parameters derived from the anal-
ysis of cell-based functional assays (see below), radioligand
binding experiments were performed on whole cells rather
than membrane preparations. Saturation binding assays were
performed using cells plated at 104 cells per well in 96-well
Isoplates (PerkinElmer Life Sciences). The following day cells
were incubated with the orthosteric antagonists [3H]QNB or
[3H]NMS in a final volume of 100 l of HEPES buffer (10 mM
HEPES, 145 mM NaCl, 1 mM MgSO47H2O, 10 mM glucose, 5
mMKCl, 2 mMCaCl2, 1.5 mMNaHCO3, pH 7.4) for 2 h at room
temperature. For competition binding assays, cells were plated
at 2.5  104 cells per well. The following day, cells were incu-
bated in a final volume of 100 l of HEPES buffer containing
increasing concentrations of the competing cold ligandCCh (in
the absence or presence of increasing concentrations of BQCA)
for 4 h at 4 °C (to avoid potential confounding effects of com-
peting agonist ligands on receptor internalization while ensur-
ing reactions reach equilibrium) in the presence of 0.3 nM
[3H]QNB or [3H]NMS. Nonspecific binding was defined in the
presence of 100 M atropine. For all experiments, termination
of the assay was performed by rapid removal of radioligand
followed by two 100-l washes with ice-cold 0.9% NaCl buffer.
Radioactivity was determined by addition of 100 l of Micros-
cint scintillation liquid (PerkinElmer Life Sciences) to eachwell
and counting in a MicroBeta plate reader (PerkinElmer Life
Sciences).
IP-One Accumulation Assays—The IP-One assay kit (Cisbio,
France) was used for the direct quantitative measurement of
myoinositol 1-phosphate (IP1) in FlpIn CHO cells stably
expressing either WT or mutant hM1 mAChRs. This is a com-
petitive immunoassay that measures the homogeneous time-
resolved fluorescence signal transferred between a cryptate-la-
beled IP1-specificmonoclonal antibody and d2-labeled IP1. The
fluorescence signal measured is inversely proportional to the
concentration of native IP1.
Briefly, cells were seeded into 384-well proxy-plates at 7,500
cells per well and allowed to grow overnight at 37 °C, 5% CO2.
The following day, cells were stimulated with CCh in IP1 stim-
ulation buffer (HEPES 10 mM, CaCl2 1 mM, MgCl2 0.5 mM, KCl
4.2 mM, NaCl 146 mM, glucose 5.5 mM, LiCl 50 mM, pH 7.4) in
the absence or presence of increasing concentrations of BQCA
and incubated for 1 h at 37 °C, 5% CO2. Cells were lysed by the
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addition of homogeneous time-resolved fluorescence reagents,
the cryptate-labeled anti-IP1 antibody, and the d2-labeled IP1
analog prepared in lysis buffer, followed by incubation for 1 h at
room temperature. The emission signals were measured at 590
and 665 nm after excitation at 340 nm using the Envision mul-
tilabel plate reader (PerkinElmer Life Sciences), and the signal
was expressed as the homogeneous time-resolved fluorescence
ratio: F  ((fluorescence665 nm/fluorescence590 nm)  104).
Experiments usingWTM1mAChR CHO FlpIn cells were per-
formed in parallel each day.
ComputationalMethods for theModel of the Ligand-Receptor
Complex—The sequence of the hM1 mAChR was retrieved
from the Swiss-Prot database. ClustalX software (21) was used
to align the hM1mAChR sequence with the crystal structure of
the nanobody-stabilized active state of the human 2 adreno-
receptor (Protein Data Bank code 3P0G) (22). Ballesteros-
Weinstein numbering was used for residues in the TMs (23).
The structural model of the receptor was built using the
Modeler Version 9.12 suite of programs (24), which yielded 10
candidate models. The conserved disulfide bonds between res-
idues Cys-983.25 at the top of TMIII and the cysteine in the
middle of the ECL2 as well as the one between Cys-3916.61 and
Cys-3947.29 in ECL3 present in the template structure were also
built and maintained as a constraint for geometric optimiza-
tion. The best structure was selected from these candidates,
according to the Modeler Discrete Optimized Protein Energy
(DOPE) assessment score and visual inspection. The resulting
receptor structure was optimized using the Duan et al. (25)
force field and the general Amber force field, and HF/6–31G*-
derived restrained electrostatic potential atomic charges were
used for the ligands (26).
Docking of the ligands was performed withMOE (Molecular
Operating Environment, Chemical Computing Group, Inc.).
CCh was docked manually into the receptor model with the
protonated nitrogen interacting with Asp3.32 and the carba-
mate group situated toward TMVI resembling the position of
the ligands described in the mAChR crystal structures (Protein
Data Bank code 3UON (7) and Protein Data Bank code 4DAJ
(11)). The allosteric binding site of BQCA was generated using
the Alpha site finder. Dummy atoms were created from the
obtained  spheres. BQCA docking was carried out using the
Induced Fit protocol, with Alpha PMI placement and Affinity
dG rescoring. One main BQCA pose was obtained at an allo-
steric site comprising residues from ECL2, ECL3, TMII, and
TMVII at the extracellular surface of theM1mAChR. The low-
est energy conformation of this posewas selected and subjected
to an energyminimization usingMMFF94X force field. Molec-
ular dynamics (MD) simulations of the final complex was
performed with NAMD2.9 (27) package using the protocol
described previously (28).
Data Analysis—All data were analyzed using Prism 6.01
(GraphPad Software, San Diego). Inhibition binding curves
between [3H]QNB or [3H]NMS and unlabeled ligands were fit-
ted to a one-site bindingmodel (29). Binding interaction studies
with allosteric ligands were fitted to the following allosteric
ternary complex model, Equation 1 (30),
Y 
Bmax[A]
A  KAKBB KB1 IKI  BKB  IBKIKB 
(Eq. 1)
whereY is percentage (vehicle control) binding;Bmax is the total
number of receptors; [A], [B], and [I] are the concentrations of
radioligand, allosteric modulator, and the orthosteric ligand,
respectively; KA, KB, and KI are the equilibrium dissociation
constants of the radioligand, allosteric modulator, and
orthosteric ligand, respectively.  and  are the binding coop-
erativities between the allosteric modulator and radioligand
and the allosteric ligand and orthosteric ligand, respectively.
Values of  (or )1 denote positive cooperativity; values1
(but0) denote negative cooperativity, and values 1 denote
neutral cooperativity.
Concentration-response curves for the interaction between
the allosteric ligand and the orthosteric ligand in the various
functional signaling assays were globally fitted to the following
operational model of allosterism and agonism, Equation 2 (20),
E 
Em	AA	KB  B
  BBKA

n
	AKB  KAKB  BKA  AB

n
 	AA	KB  B
  BBKA

n
(Eq. 2)
where Em is the maximum possible cellular response; [A] and
[B] are the concentrations of orthosteric and allosteric ligands,
respectively; KA and KB are the equilibrium dissociation con-
stant of the orthosteric and allosteric ligands, respectively; A
and B are operational measures of orthosteric and allosteric
ligand efficacy, respectively;  is the binding cooperativity
parameter between the orthosteric and allosteric ligand, and 
denotes the magnitude of the allosteric effect of the modulator
on the efficacy of the orthosteric agonist. Inmany instances, the
individualmodel parameters of Equation 2 could not be directly
estimated via the nonlinear regression algorithm by analysis of
the functional data alone, due to parameter redundancy. To
facilitate model convergence, we therefore fixed the equilib-
rium dissociation constant of each ligand to that determined
from the whole cell binding assays. This practice assumes that
the affinity determined in the whole cell binding assays is not
significantly different from the “functional” affinity operative at
the level of the signaling assay, whichmaynot always be the case
(31), and thusmay lead to a systematic error in the estimate of the
operational efficacy parameter, . However, because only a single
pathway (IP1) is being considered, the relativedifferences between
 values remain valid for statistical comparison purposes.
All affinity, potency, and cooperativity values were estimated
as logarithms (32), and statistical comparisons between values
were by one-way analysis of variance using aDunnett’smultiple
comparison post test to determine significant differences
between mutant receptors and theWTM1mAChR. A value of
p 0.05 was considered statistically significant.
RESULTS
To identify the location of the binding pocket of BQCA and
to gain insight into its molecular mechanism of allosteric mod-
ulation at the M1 mAChR, residues from distinct locations
Structure-Function Analysis of M1 Receptor Allostery
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within the receptor were mutated to alanine (Fig. 1). This
includes residues previously shown to be important for
orthosteric, allosteric, or bitopic ligand binding at either theM1
or other mAChR subtypes (18, 33–35).
Effects of Amino Acid Substitutions on the Binding of
Orthosteric Ligands at the M1 mAChR—Whole cell [3H]NMS
saturation binding experiments showed that themajority of the
mutations led to a significant reduction in cell surface receptor
expression compared with the WT (Table 1). The maximum
decrease in receptor expression relative to WT was 3-fold at
F3746.44A. In agreement with previous reports (36, 37), no
[3H]NMS binding was detected when residues Tyr-1063.33,
Trp-1574.57, Tyr-3816.51, or Val-395 were mutated to alanine.
For these mutant receptors, [3H]QNB was used as the alterna-
tive radioligand.
In addition to receptor expression, the equilibrium dissocia-
tion constant of orthosteric antagonists [3H]NMS or [3H]QNB
(pKA) or the orthosteric agonist CCh (pKI) were significantly
altered for a large number of mutants (Fig. 2 and Tables 1 and
2). Most notably, and in agreement with previous studies (33,
37, 38), alanine mutation of the TMII residues Tyr-822.61 or
Tyr-852.64, and the conserved orthosteric site residues Trp-
1013.28, Leu-1023.29, Asp-1053.32, Tyr-1063.33, Trp-1574.57, Thr-
1895.39, or Thr-1925.42 caused significant reduction in the equi-
librium dissociation constants of both CCh and the
radiolabeled antagonist used (Fig. 2 and Tables 1 and 2). Muta-
tion of Leu-183 in ECL2 or Val-395 in ECL3 also led to signifi-
cant decreases in the affinities of both ligands. Consistent with
previous findings showing that theTyr-3816.51 residue is able to
discriminate between differentmAChR antagonists (39, 40), we
found that Y3816.51A completely abolished [3H]NMS binding,
although it showed unaltered affinity for [3H]QNB. Several
mutations showed differential effects between the binding of
the radioligand and CCh. F182A and E3977.32A caused signifi-
cant reduction in [3H]NMS affinity but had no effect upon the
affinity of CCh, whereas I180A and W4007.35A only decreased
CCh affinity. Mutation of the highly conserved aromatic resi-
dues Phe-3746.44 and Trp-4057.40 as well as the ECL2 residue
Gln-181 resulted in substantially enhanced CCh binding affin-
ity, with F3746.44A also displaying reduced [3H]NMS binding.
Mutation of Phe-3746.44 and Trp-4057.40 to alanine has been
previously shown to cause constitutive receptor activity, which
is likely to account for the increase in CCh affinity (38, 40–43).
Alanine substitution of Tyr-179, Ser-1845.32, Lys-392, and Glu-
4017.36 did not impact the affinity of either agonist or antago-
nist. Overall, the change in pKA of the radiolabeled antagonists
tracks with changes in CCh pKI for the majority of mutations
FIGURE1.Mutationsand ligands investigated in this study.A snakediagramof thehumanM1mAChRhighlightingmutated residues andchemical structure
of the allosteric modulator BQCA.
TABLE 1
Whole cell equilibrium saturation binding parameters for WT and
mutant M1 mAChRs
Values represent the mean  S.E. from 2 to 5 separate experiments performed in
duplicate. Bmax is the maximum density of binding sites per 104 cells in counts/min.
pKA is the negative logarithm of the radioligand equilibrium dissociation constant.
Bmax pKA
M1 WT 3HNMS 300 10 10.04 0.01
M1 WT 3HQNB 290 13 9.85 0.03
Y822.61A 225 7 9.76 0.01a
T832.62A 302 5 9.95 0.05
Y852.64A 398 10 9.82 0.03a
W1013.28A 177 1a 9.36 0.06a
L1023.29A 147 12a 9.40 0.05a
D1053.32E 195 12a 9.17 0.07a
Y1063.33Ab 220 10 9.15 0.20a
W1574.57Ab 300 8 9.32 0.09a
Y179A 270 14 10.00 0.02
I180A 186 6a 9.95 0.03
Q181A 276 8 9.92 0.08
F182A 255 7 9.52 0.05a
L183A 300 23 9.31 0.05a
S1845.32A 246 9a 10.04 0.02
T1895.39A 390 13a 9.56 0.08a
T1925.42A 402 12a 9.76 0.05a
F3746.44A 90 8a 9.29 0.12a
Y3816.51Ab 174 15a 9.82 0.02
K392A 231 7 9.88 0.09
V395Ab 315 24 9.30 0.06a
E3977.32A 237 8a 9.82 0.02a
W4007.35A 138 6a 9.95 0.01
E4017.36A 236 18a 9.97 0.05
W4057.40A 189 10a 9.95 0.02
a Data are significantly different (p 0.05) fromWT value as determined by one-
way analysis of variance with Dunnett’s post hoc test.
b Experiments and statistical comparisons are relative to WT 3HQNB values.
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tested (Fig. 2). Those that showed the most divergent effects
include Y3816.51A in the orthosteric pocket, causing a marked
decrease in CCh affinity but not that of [3H]QNB and Q181A,
F3746.44A, and W4057.40A that caused an increased affinity for
CCh.
Effect of Amino Acid Substitution on BQCA Affinity and on
the Transmission of Binding Cooperativity with CCh at the M1
mAChR—The orthosteric binding pocket is formed by amino
acids that are fully conserved across all five mAChR subtypes
(7). However, although the importance of these residues for
orthosteric ligand binding has been demonstrated in numerous
studies and confirmed in our results, less is known about the
role of these residues in the actions of allosteric ligands. Muta-
tion of Trp3.28 at the M2 and M4 mAChRs led to a significant
reduction in affinity of the allostericmodulator LY2033298 and
its binding cooperativity with ACh (14, 33). To determine
whether BQCA behaves in a similar manner to LY2033298 at
the equivalent residue in the M1 mAChR, we performed equi-
librium binding studies for the interaction between CCh and
BQCA atW1013.28A, as well as at other orthosteric pocket res-
idues. An allosteric ternary complex model (Equation 1) was
applied to the data to obtain estimates of BQCA affinity at each
mutant (pKB), and its binding cooperativity with CCh (log )
(representative examples of the analysis for different constructs
are shown in Fig. 3, and all results are summarized in Fig. 4).
We found that the cooperativity of BQCA with CCh at
W1013.28A, L1023.29A, or T1925.42A was not significantly dif-
ferent when compared with the WT receptor estimates (Fig. 4
and Table 2). Although these residues do not form direct con-
tacts with orthosteric ligands, they have been described to con-
stitute a “second shell” that stabilizes the primary binding
pocket (3, 44). Interestingly, mutation of orthosteric binding
site residues substantially affected the ability of BQCA to mod-
ulate CCh affinity; binding cooperativity with CCh was com-
pletely abolished at Y1063.33A, W1574.57A, and Y3816.51A and
was significantly reduced at D1053.32E and T1895.39A (Figs. 3D
and 4 and Table 2). In addition, V395A, which displayed a
reduction in affinity for [3H]QNB and CCh similar to that of
orthosteric site residues, also caused a significant reduction in
binding cooperativity between BQCA and CCh (Table 2 and
Fig. 4 (bottom panel)). No pKB estimates for BQCA could be
derived from the analysis of the binding interaction data of
Y1063.33A,W1574.57A, or Y3816.51A due to the lack of allosteric
modulation. The pKB of BQCA was significantly lower than
WT at L1023.29A and D1053.32E but was unchanged at the
remaining orthosteric site mutations (Fig. 4 (top panel) and Table
2). These results suggest that residues that form direct contacts
with theorthosteric ligand(7)alsoplaya role in the transmissionof
cooperativity from the allosteric binding site of BQCA.
Equilibrium binding studies for the interaction between CCh
and BQCAwere also performed on residues previously described
to participate in the allosteric modulation of mAChRs. Alanine
FIGURE 2. Orthosteric agonist affinity estimates are differentially modi-
fied by M1 mAChR mutations. Bars represent the difference in pKA of
orthosteric antagonist [3H]NMS or [3H]QNB (top panel) derived from whole
cell saturation binding experiments (Table 1) or the difference in pKI of the
orthosteric agonist CCh (bottom panel) derived from whole cell competition
binding experiments (Table 2), relative to the WT receptor value for each
ligand at eachmutant residue. Data represent themean S.E. of three exper-
iments performed in duplicate. *, significantly different from WT, p  0.05,
one-way analysis of variance, Dunnett’s post hoc test.
TABLE 2
Whole cell equilibrium competition binding parameters for the inter-
action between 3HNMS or 3HQNB, CCh, and BQCA at the WT and
mutant M1 mAChRs
Estimated parameter values represent the mean  S.E. of 3–4 experiments per-
formed in duplicate and analyzed according to Equation 1.
CCh pKIa BQCA pKBb log c
M1 WT 3HNMS 4.56 0.05 4.49 0.09 2.64 0.12
M1 WT 3HQNB 4.67 0.20 4.18 0.18 2.31 0.36
Y822.61A 3.89 0.10d 4.70 0.08 2.53 0.14
T832.62A 4.62 0.12 4.39 0.18 2.52 0.24
Y852.64A 3.84 0.08d 4.32 0.10 2.29 0.13
W1013.28A 3.64 0.10d 4.38 0.06 2.43 0.11
L1023.29A 3.21 0.06d 4.12 0.10d 2.19 0.12
D1053.32E 3.09 0.08d 3.79 0.07d 1.61 0.1d
Y1063.33Ae 1.73 0.10d NDf ND
W1574.57Ae 1.85 0.06d ND ND
Y179A 4.63 0.07 4.55 0.11 0.52 0.20d
I180A 4.07 0.08d 5.03 0.08d 2.49 0.13
Q181A 5.42 0.05d 5.12 0.07d 1.79 0.1d
F182A 4.68 0.03 4.41 0.07 1.79 0.12d
L183A 3.51 0.03d 4.23 0.05 2.32 0.08
S1845.32A 4.35 0.09 4.70 0.1 2.27 0.15
T1895.39A 3.69 0.07d 4.68 0.04 1.73 0.11d
T1925.42A 3.22 0.08d 4.06 0.13 2.18 0.15
F3746.44A 5.43 0.08d 5.38 0.06d 1.57 0.15d
Y3816.51Ae 2.46 0.06d ND ND
K3926.62A 4.28 0.05 4.40 0.09 2.80 0.12
V3957.30Ae 2.03 0.06d 4.31 0.06 1.02 0.25d
E3977.32A 4.64 0.07 4.66 0.07 1.79 0.13d
W4007.35A 4.18 0.02d ND ND
E4017.36A 4.60 0.12 4.72 0.08 1.74 0.14d
W4057.40A 5.40 0.07d 5.70 0.05d 1.59 0.12d
aNegative logarithm of the equilibrium dissociation constant of CCh.
bNegative logarithm of the equilibrium dissociation constant of BQCA as esti-
mated from Equation 1.
c Logarithm of the binding cooperativity factor between BQCA and CCh as esti-
mated from Equation 1; for this analysis, the pKA of the radiolabeled antagonist
for the WT and each of the mutant receptors was constrained to the values
listed in Table 1. The cooperativity between BQCA and the radioligand was
constrained to2, consistent with high negative cooperativity between the two
ligands.
d Data are significantly different (p 0.05) fromWT values as determined by one-
way analysis of varianc with Dunnett’s post hoc test.
e Experiments and statistical comparisons are relative to WT 3HQNB values.
f NDmeans not determined (no modulation of affinity).
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substitution of the TMII residues had no affect on the binding
cooperativity between BQCA and CCh (Table 2). However, ala-
nine substitution of the ECL2 residues Tyr-179, Gln-181, and
Phe-182 significantly reduced the binding cooperativity, with
Tyr-179 having the most profound effect (Fig. 3, B and C, and
Table 2). The cooperativity was unaffected at the remaining
ECL2 residues I180A, L183A, and S184A (Table 2). However,
although I180A did not have a significant effect on cooperativ-
ity, it had significant opposing effects on the affinities of CCh
and BQCA, with a decrease in the former and an increase in the
latter (Figs. 2 and 4 and Table 2).
Mutation of the glutamate residues Glu-3977.32 and Glu-
4017.36, which have been implicated in the binding of allosteric
ligands at the mAChRs (34, 45, 46), also caused significant
reduction in the binding cooperativity (Table 2). Alanine sub-
stitution of the conserved Trp-4007.35 residue in TMVII led to
complete loss of allosteric modulation even at the highest con-
centrations of BQCA (Fig. 3E and Table 2) confirming the
importance of this residue for the binding of allosteric ligands at
the M1 mAChR (18, 40, 47) and suggesting that this is likely to
be a residue with which BQCA directly interacts.
Alanine substitution of the conserved aromatic residues Phe-
3746.44 or Trp-4057.40 also led to substantial reductions in the
binding cooperativity (Fig. 3F and Table 2). Interestingly all
threemutations (Q181A, F3746.44A, andW4057.40A) that led to
an increase in CCh affinity also caused an increase in BQCA
affinity and a reduction in the binding cooperativity between
the two ligands (Figs. 2, 3F, and 4 and Table 2). The pKB esti-
mates obtained from the binding interaction studies at the
remaining mutants were not significantly different from WT
(Fig. 4 and Table 2). Overall, the binding interaction studies
revealed a significant correlation between the changes in affin-
FIGURE3. Identificationof residues thatdifferentially governBQCAaffinity andbinding cooperativitywithCChat theM1mAChR. The curves represent
competition between [3H]NMS (A–C, E, and F) or [3H]QNB (D) and increasing concentrations of CCh in the absence or presence of varying concentrations of
BQCA. All assays were performed using 0.3 nM [3H]NMS or [3H]QNB in whole cells expressing theWT or mutant c-Myc-taggedM1 mAChRs as described under
“Experimental Procedures.”Datapoints represent themeanS.E. of three independent experimentsperformed induplicate. Curvesdrawn through thepoints
in A–C and F represent the best fit of an allosteric ternary complex model (Equation 1). Parameters obtained from these experiments are listed in Table 2.
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ities of CCh and BQCA (Fig. 5). Additionally, these data show
that residues located in both the putative allosteric and the
orthosteric pockets are conformationally linked and contribute
to the transmission of binding cooperativity.
Effects of Mutations on Ligand Efficacy and on the Transmis-
sion of Functional Cooperativity between CCh and BQCA—To
investigate the effects of the selectedmutations on the ability of
BQCA to modulate signaling efficacy, we determined the con-
centration-response profile for CCh in the absence and pres-
ence of increasing concentrations of BQCA using IP1 accumu-
lation as a canonical measure of M1 mAChR activation
resulting from preferential activation of Gq G proteins. The
potency (pEC50) and maximal agonist effect (Emax) parameters
for CCh in the absence of modulator are shown in Table 3. As
agonist potency is determined by affinity, signaling efficacy, and
receptor density, we applied an operational model of alloster-
ism (Equation 2 (20)) to estimate the effect of each mutation
on the operational efficacy (log ) of CCh and BQCAwithout
the confounding influence of affinity. The estimated log 
values were then corrected for changes in receptor expres-
sion and are summarized in Fig. 6 and Table 4. Additionally,
analysis of the data with Equation 2 allowed for the estima-
tion of the overall functional allosteric interaction between
CCh and BQCA at each mutant (denoted by the parameter
log ).
As summarized in Fig. 6 (representative examples in Fig. 7),
the majority of the M1 mAChR mutations led to a significant
reduction in the signaling efficacy of CCh (log A). Not surpris-
ingly, the most prominent effects were seen for the orthosteric
site residues in TMIII, W1574.57A in TMIV, and Y3816.51A in
TMVI, consistent with reduced CCh affinity at these mutants
and their importance for orthosteric ligand binding (3). No
change in log A was detected at residues for which CCh dis-
played higher affinity (Q181A, F3746.44A, and W4057.40A).
Interestingly, our analysis indicated that the CCh log A was
significantly larger than WT at V395A in ECL3, despite a sig-
nificant reduction in CCh binding affinity (Figs. 2 and 6 and
Tables 1 and 2). BQCA agonism was not detected at any of the
mutants with the exception of F3746.44A (log B 0.55  0.10)
and W4057.40A (log B 0.25  0.06), where log B was not sig-
nificantly different to WT (log B 0.38 0.05) (Fig. 7).
FIGURE 4. Effects of M1 mAChR mutations on BQCA affinity and binding
cooperativity estimates. Bars represent the difference in pKB (top panel) or
binding cooperativity value (log , bottom panel) of BQCA relative to WT as
derived from binding interaction experiments with CCh (Table 2). Data rep-
resent the mean S.E. of three experiments performed in duplicate. ND, no
modulation by BQCA. *, significantly different from WT, p  0.05, one-way
analysis of variance, Dunnett’s post hoc test.
FIGURE 5. Positive correlation between the changes in orthosteric and
allosteric ligand affinities at the M1 mAChR mutants. Each point repre-
sents the affinity values of BQCA (pKB) and CCh (pKI) as determined from
whole cell competition binding studies as listed in Table 2.
TABLE 3
CCh pEC50 and Emax values for WT and mutant M1 mAChRs as mea-
sured from the IP1 accumulation assay
Estimated parameter values represent the mean  S.E. of three experiments per-
formed in duplicate.
pEC50a Emax
WT 5.72 0.08 100
Y822.61A 4.65 0.20b 66.03 7.35b
T832.62A 5.27 0.15 20.39 1.35b
Y852.64A 4.43 0.06b 90.56 5.67
W1013.28A 2.95 0.50b 10.05 3.40b
L1023.29A 2.46 0.10b 20.00 5.37b
D1053.32E NAc NA
Y1063.33A NA NA
W1574.57A NA NA
Y179A 4.39 0.14b 82.38 4.47
I180A 4.43 0.27b 79.92 9.37
Q181A 5.120 0.26 80.00 7.60
F182A 4.85 0.10b 82.73 3.85
L183A 3.76 0.14b 65.32 5.11b
S1845.32A 4.89 0.07b 85.55 4.00
T1895.39A 3.94 0.15b 101.00 9.41
T1925.42A 3.40 0.20b 70.82 9.24
F3746.44A 4.74 0.09b 105.2 3.55
Y3816.51A 3.10 0.30b 21.81 3.00b
K3926.62A 5.37 0.12 91.19 5.66
V3957.30A 4.71 0.11b 97.23 4.45
E3977.32A 5.50 0.21 96.20 8.89
W4007.35A 3.50 0.08b 71.80 3.70
E4017.36A 5.12 0.05 99.00 3.39
W4057.40A 5.21 0.05 84.38 1.98
aNegative logarithm of the EC50 value.
b Significantly different (p 0.05), fromWT value as determined by one-way
analysis of variance with Dunnett’s post hoc test.
cNA, not applicable (no detectable response).
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Acommon findingwas obtained from the interaction studies
between BQCA and CCh at the orthosteric site mutations that
substantially impaired CCh signaling (W1013.28A, L1023.29A,
D1053.32E, Y1063.33A, W1574.57A, and Y3816.51A). As opposed
to the loss of cooperativity between the two ligands seen in the
binding interaction studies for the majority of these mutant
receptors (Fig. 3D and Table 2), BQCA was able to rescue CCh
function (Fig. 7D and Table 4). An analogous “rescue” of ACh
function by LY2033289 has been described at equivalent TMIII
residues in the M4 mAChR (33, 48). This finding indicates that
a key part of themechanism for the positive cooperativitymedi-
ated by BQCA on the orthosteric agonist involves a global drive
of the receptor toward an active conformation.
The majority of mutant residues that displayed reduced
binding cooperativity (log ) between CCh and BQCA also
caused a reduction in functional cooperativity (log) between
the two ligands (Fig. 8). These include the three residues that
showed enhanced affinities for CCh and BQCA (Q181A,
W4057.40A, and F3746.44A), F182A in ECL2 (Fig. 7, C and F),
T1895.39A in TMV, and the two glutamate mutants E3977.32A
and E4017.36A. The three residues mutated in TMII (Y822.61A,
T832.62A, and Y852.64A) and L183A in ECL2 caused significant
reductions in functional cooperativity despite their lack of
effect on binding cooperativity between CCh and BQCA (Fig. 8
and Table 4), indicating that these residues are likely to play a
role in the transmission of functional cooperativity alone. In
contrast, the log  between BQCA and CCh at V395A was
unchanged, despite significantly reduced binding cooperativity
(Fig. 8 and Table 4). Consistent with the findings of Ma et al.
(18), modulation of CCh efficacy was absent at Y179A and
W4007.35A (Figs. 7, B and E, and 8). These results suggest that
Trp-4007.35 and Tyr-179 are likely to be residues with which
BQCA directly interacts.
Molecular Dynamics Simulations and Ligand Docking—Li-
gand docking and molecular dynamic simulations were subse-
quently performed to rationalize our findings. This resulted in
one main pose of BQCA in the predicted allosteric site.
The obtained complex for BQCA and CCh bound to the
modeledM1mAChR is shown in Fig. 9A. CCh forms the estab-
lished salt bridge between the cationic nitrogen and Asp-
1053.32 and is fixed in a hydrophobic pocket formed by residues
Tyr-1063.33 in TMIII, Trp-1574.57 in TMIV, Tyr-3816.51 in
TMVI, and Tyr-4047.39 and Tyr-4087.43 in TMVII (Fig. 9B).
This is a signature network of interactions in cationic amine
receptors (7, 11, 49), rhodopsins (51), and the adenosine A2A
receptor (52). Moreover, the orthosteric site is further flanked
by the H-bonds formed between Tyr-1063.33 and Tyr-3816.51,
which adds stability to the binding pocket (3), and togetherwith
Tyr-4047.39 and Tyr-4087.43 formed an aromatic lid separating
the orthosteric and allosteric pockets. The aromatic ring of
Trp-1574.57 appears to form a - interaction with Tyr-1063.33
(Fig. 9B), and it has been shown to form direct contact with the
aromatic ring of the antagonist QNB (7).
The analysis of the MD trajectories shows the interaction of
BQCA with residues located in the allosteric binding site (Fig.
9C). This binding site is defined by residues fromTMII, TMVII,
and ECL2 and is in agreement with our binding and functional
studies; in particular, significant effects of the mutation of Tyr-
179 in ECL2 and Trp-4007.35 in TMVII can be reconciled with
this pose. Tyr-179 is predicted to contribute to the stability of
BQCA binding via formation of hydrophobic/edge-to-face-
FIGURE 6. CCh signaling efficacy (log A) estimates are differentially
affected byM1mAChRmutations. Bars represent the difference in log A of
CCh at each mutant relative to the WT receptor value, as derived from appli-
cation of the operational model of allosterism to the IP1 interaction data at
each mutant (Equation 2). Data represent the mean  S.E. of three experi-
ments performed in duplicate. NR indicates that CCh activity was absent. ND
indicates that Equation 2 could not be used due to loss of allosteric modula-
tion by BQCA. *, significantly different to WT receptor value, p  0.05, one-
way analysis of variance, Dunnett’s post hoc test.
TABLE 4
Operationalmodelparameters for the functional allosteric interaction
between CCh and BQCA at theWT andmutant M1mAChRs measured
using IP1 accumulation
Estimated parameter values represent the mean  S.E. of three experiments per-
formed in duplicate. Log A and log  values were obtained from analyses of
functional interaction data according to Equation 2. For this analysis, the pKI and
pKB values for CCh and BQCA, respectively, were fixed to those determined from
the radioligand binding assays as listed in Table 2.
log Aa log b
WT 1.32 0.07 2.03 0.12
Y822.61A 1.21 0.13 1.14 0.17c
T832.62A 0.65 0.13c 0.73 0.20c
Y852.64A 0.53 0.07c 1.03 0.09c
W1013.28Ad 1.11 0.18c 1.95 0.17
L1023.29Ad 0.44 0.24c 0.98 0.15c
D1053.32Ed 0.69 0.23c 0.97 0.20c
Y1063.33Ad 0.79 0.21c 1.24 0.10c
W1574.57Ad 2.01 0.20c 1.74 0.49
Y179A NDe ND
I180A 0.89 0.13 1.35 0.18
Q181A 0.24 0.08c 0.33 0.12c
F182A 0.70 0.07c 0.53 0.13c
L183A 0.52 0.11c 1.26 0.13c
S1845.32A 1.01 0.11 1.61 0.14
T1895.39A 0.25 0.18c 0.71 0.12c
T1925.42A 0.23 0.11c 1.76 0.10
F3746.44A 0.56 0.11c 0.03 0.02c
Y3816.51Ad 0.23 0.11c 1.25 0.08c
K3926.62A 1.16 0.11 1.92 0.14
V3957.30A 2.19 0.10c 1.46 0.14
E3977.32A 1.17 0.20 1.07 0.30c
W4007.35A ND ND
E4017.36A 0.74 0.02c 0.93 0.04c
W4057.40A 0.38 0.02c 0.47 0.07c
a Logarithm of operational efficacy parameter for CCh (log A) was corrected for
changes in receptor expression to allow comparison with WT.
b Logarithm of the functional cooperativity between CCh and BQCA is shown.
c Significantly different (p 0.05), fromWT value as determined by one-way
ANOVA with Dunnett’s post hoc test.
d pKB of BQCA was left unconstrained at W101A, L102A, D105E, Y106A, W157A,
and Y381A. The log B of BQCA was constrained to2 at these mutants.
eND, no modulation by BQCA.
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interactions with both the bicyclic 4-oxoquinoline core and the
benzylic pendant of BQCA. Similarly, Trp-4007.35 is predicted
to make a - interaction with the benzylic pendant. In this
model, Glu-3977.32 also constrains this moiety of BQCA
through a hydrophobic interaction, essentially forming a lid
over this part of the allosteric binding site. Tyr-852.64 and Tyr-
822.61 are predicted to delimit the allosteric site via extra edge-
to-face -/hydrophobic interactions with the 4-oxoquinoline
ring system (Fig. 9C). Although the former residue only affected
the functional cooperativity between BQCA and CCh, it has
been found to be an important contact residue for prototypical
allosteric modulators at the M2 mAChR (13). Mutation of an
adjacent residue at the M4 mAChR (I932.65T) was found to be
important for the transmission of cooperativity between ACh
and LY2033298 (34), suggesting a contribution of this residue
to a conserved allosteric pocket within the mAChR family. Fig.
10 shows the global movements of the ECLs and TMs as well as
the movements of the residues to accommodate the binding of
BQCA. These include the rotation of the aromatic side chains
of Trp-4007.35 (Fig. 10, inset) and Trp-4057.40 that may be facil-
itating the accompanying shifts in the nearby TMVII residues
Glu-3977.32 and Glu-4017.36 to constrain BQCA into the
observed pose. The binding of BQCA also causes subtle move-
ments in the ECLs; the most significant of these appear to be in
ECL2 where the aromatic side chains of Tyr-179 and Phe-182
bothmove closer to BQCA, whereas Gln-181 adopts a horizon-
tal position away from the ligand accessible cavity. These
results support our finding that mutation of Glu-3977.32, Glu-
4017.36, Tyr-179, and Phe-182 lead to reduced cooperativity
between BQCA and CCh and that mutation of Gln-181
enhances the binding affinity of both ligands.
FIGURE 7. Identification of residues that differentially govern BQCA efficacy and functional cooperativity with CCh at the M1 mAChR. Interaction
between BQCA and CCh in IP1 accumulation assay in CHO FlpIn cells stably expressing the WT or mutant M1 mAChRs. Data points represent the mean S.E.
of three independent experiments performed in duplicate. Curves drawn through the points in A, C, D, and F represent the best fit of an operational
allosteric model (Equation 2 and Table 4) with the affinity of each ligand at each mutant fixed to the value determined from separate binding studies
(Table 2).
FIGURE 8. BQCA functional cooperativities are differentiallymodified by
M1mAChRmutations. Bars represent the difference in the functional coop-
erativity value (log , Equation 2) relative to the WT value, as derived from
application of the operational model of allosterism to the CCh and BQCA IP1
interaction data at each mutant (Equation 2) (Table 4). Data represent the
mean S.E. from three experiments performed in duplicate.ND, nomodula-
tion by BQCA. * significantly different fromWT value, p 0.05, one-way anal-
ysis of variance, Dunnett’s post test.
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DISCUSSION
BQCA demonstrates a number of unique properties relative
to previously described allosteric ligands of the mAChR family,
including an exquisite selectivity for M1 mAChRs over other
subtypes and a mechanism of action that appears in strict
accordance with a two-state model of receptor activity, such
that it is a positive modulator of agonists but a negative modu-
lator of antagonists/inverse agonists (16, 17). Moreover, the
compound is active in vivo (18, 53), providing proof of concept
for the validity of allosteric targeting of M1 mAChRs in the
treatment ofCNSdisorders, and it has been the focus of numer-
ous structure-activity studies (15, 54) aimed at improving its
“druggability” and affinity. However, it is now apparent that
allosteric modulators can achieve selectivity by more than one
mechanism, i.e. at the level of structural divergence of an allo-
steric pocket across GPCR subtypes or via selective cooperativ-
FIGURE 9. Structural model of the M1mAChR in complex with BQCA and CCh. A, overall view of the complex obtained using MD simulations. The ligands
are shown in orange (BQCA) and yellow (CCh) spheres. B, orthosteric binding site for CCh; C, predicted allosteric binding site of BQCA. Important residues are
shown by orange sticks.
FIGURE 10.Proposed rearrangementof ECLs andTMsuponBQCAbinding toM1mAChR. Extracellular viewof the BQC-binding site at the startingposition
for MD simulations (gray) or at the final position of the receptor after 20 ns of MD (orange). Important residues involved in BQCA binding or cooperativity are
shown as sticks. Global movements of TMs and ECLs are shown with green arrows, and residue shifts are indicated by blue arrows. Inset shows the movement
of the side chain of Trp-4007.35.
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ity at a given subtype despite acting at a “conserved” allosteric
site (14). The latter paradigm is best exemplified by the
mAChRs, in which are all characterized by an extracellular ves-
tibule that can be recognized by structurally diverse allosteric
ligands (12, 13). To better understand the basis of the selectivity
of BQCA, we combined mutagenesis with mathematical and
molecular modeling to identify potential structural contribu-
tors to its binding pocket and its ability to allosterically modu-
late the binding and signaling of the prototypical orthosteric
agonist CCh.
Although no affinity values could be obtained for BQCA at
residues where allosteric modulation was abolished (Tyr-
1063.33, Trp-1574.57 andTyr-3816.51 andTrp-4007.35), our study
identified residues of the M1 mAChR that contribute to the
following: (i) the binding affinity of themodulator; (ii) the coop-
erativity between the modulator and the orthosteric agonist
CCh; (iii) the ability of the modulator to drive the receptor into
an active state, and (iv) enhancement of the binding affinity of
BQCA.
Alanine substitution of a number of residues from various
regions in the receptor caused a decrease in the cooperativity
between BQCA and CCh in binding and functional interaction
studies (Figs. 4 and 8 and Tables 2 and 4). Such reductions in
cooperativity resulted either from mutation of residues that
form the proposed allosteric binding pocket or residues confor-
mationally linked to the allosteric site and thus needed for the
transmission of cooperativity or receptor activation upon
ligand binding. Our MD simulations support this hypothesis
and the experimental findings. As shown in Fig. 9, the proposed
BQCA pocket is topographically distinct from the orthosteric
binding site, and these two sites are separated by a shelf of
aromatic residues. The residues that are predicted to form the
BQCA binding pocket, mainly from ECL2 (Tyr-179), TMII
(Tyr-852.64), andTMVII (Trp-4007.35) or thosewhosemutation
to alanine cause significant decreases in cooperativity (Phe-182,
Glu-3977.32, and Glu-4017.36), are equivalent to residues that
have been implicated in the binding of several allosteric ligands
at mAChRs, as follows : (i) the action of gallamine and the allo-
steric antagonistMT7 at theM1mAChR (40, 47); (ii) the action
of LY2033298 at the M4 mAChR (34), and (iii) the action of
C7/3-phth, gallamine, alcuronium, McN-A-343, alkane-bisam-
monium, and caracurineV-type allostericmodulators at theM2
mAChR (13, 35, 42, 55–57).
The only residue in the proposed BQCA binding pocket that
leads to complete loss of modulation in both functional and
binding assays is Trp-4007.35. This suggests that the - inter-
action of the benzylic pendant of BQCA and the aromatic side
chain of Trp-4007.35 makes either a major contribution to
BQCA binding and/or maintaining the structure of the local
binding pocket of BQCA.Other residues, such as Tyr-179, Tyr-
822.61, andTyr-852.64, while predicted in ourMDsimulations to
interact with BQCA, appear to have a predominant role in the
transmission of BQCA’s modulator action on orthosteric
ligands such that their mutation to alanine impairs the trans-
mission of cooperativity but does not lead to a significant loss of
binding affinity. Of interest, a recent molecular dynamics study
identified two binding centers in the extracellular vestibule of
the M2 mAChR, each defined by a pair of aromatic residues
(center 1, Tyr-177ECL2 and Trp7.35; center 2, Tyr2.61 and
Tyr2.64) (13). It is noteworthy that we identified these residues
as key contributors for the binding and function of BQCA. Fur-
thermore, Tyr2.64 and Trp7.35 are conserved across all mAChR
receptor subtypes; Tyr2.61 is conserved across all but the M3
mAChR (where it is replaced by a similarly aromatic phenyl-
alanine residue), and Tyr-179 is only present at the M1 and M2
mAChRs but is a phenylalanine at the M3 and M4 mAChRs.
This is consistent with BQCA sharing a common binding site
with other prototypical mAChR allosteric modulators. Glu-
3977.32 and Glu-4017.36 are not conserved across the mAChR
family and were predicted by our modeling experiments to
make minimal interaction with BQCA. Mutation of these resi-
dues had no effect on BQCA binding affinity but decreased
cooperativity with CCh. This suggests that such residues may
govern the subtype-specific cooperative effect of BQCA upon
orthosteric ligand binding from a conserved allosteric pocket.
The observation of a correlation between the change in CCh
binding affinity (pKI) and BQCA binding affinity (pKB) is
entirely consistent with our previous description of the
mechanism of BQCAwithin the confines of a strict two-state
model (Fig. 5) (17). Furthermore, the finding that the
orthosteric site residues shown in Fig. 9B lead to complete
loss (Y1063.33A, W1574.57A, and Y3816.51A), or significant
reduction (D1053.32A) in the binding cooperativity between
CCh and BQCA is a striking example of a conformationally
linked mechanism for the transmission of cooperativity. The
efficacy of CCh was severely reduced when each of these resi-
dues was mutated, but this was “rescued” by BQCA. Further-
more, these additional functional interaction data confirmed
the ability of BQCA to bind to this set of mutant receptors, a
conclusion that could not be drawn from the binding data
alone. This highlights the importance of using both binding and
functional assays to characterize the effect of mutations upon
allosteric ligand function.
Given that an analogous observation wasmade for the action
of the positive allosteric modulator, LY2033298, at a function-
ally impaired M4 mAChR double mutant containing the
Y1133.33C (48) or the D1123.32Emutation (33), our results indi-
cate that BQCA may share similarities in mechanism of action
and may bind to a site that is spatially conserved between the
M4 the M1 mAChRs. However, the very high selectivity of
BQCA for the M1 mAChR (as opposed to LY2033298 that acts
at both the M2 and M4 mAChRs) indicates that although the
allosteric sites of these two ligands share some epitopes, they
may engage additional distinct residues either in their mode of
binding or transmission of cooperativity to the orthosteric site.
In addition to regions of the receptor that were primarily
important for the binding of BQCA and transmission of coop-
erativity, we also identified mutations that caused a significant
enhancement in the affinities of both CCh and BQCA (Q181A,
F3746.44A, and W4057.40A). Previous studies have reported
increases in CCh affinity at Q181A (36, 40), whereas others
have reported constitutive receptor activity when residues 6.44
and 7.40 are mutated to alanine (41, 43). The movement of the
side chain of Phe6.44 is coupled to an outward movement of
TMVI upon 2-adrenergic receptor activation (58), and it has
been reported to be a microswitch in GPCR activation (50). It
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has also been suggested that Trp-4057.40 restricts thermal
motions of the extracellular domain of TMVII of mAChRs (3).
In summary, we have identified key regions in the M1
mAChR that are involved in the binding and signaling of CCh
and BQCA, and in the transmission of cooperativity between
the orthosteric and an allosteric binding site. We propose that
some of the structural determinants of these effects are analo-
gous to those of other family AGPCRs, but the unique selectiv-
ity of BQCA arises from the additional involvement of noncon-
served residues (e.g. Glu-3977.32 and Glu-4017.36) and/or
selective cooperativity with agonists at theM1mAChR. There-
fore, our results provide further understanding of the structural
basis of allostericmodulation thatmay be of general application
toGPCRdrug discovery and that can help guide themore ratio-
nal design of allosteric ligands that target this distinct site. In
particular, they challenge an important concept often associ-
ated with allosteric targeting of GPCRs, namely that selective
modulators gain subtype selectivity through their binding to a
site that is not conserved across a receptor subfamily. Rather, as
highlighted in our study, selective cooperativity via interaction
with a conserved allosteric site is also possible. Given the
increasing number of GPCR crystal structures now being
solved, it should thus be appreciated that structure-based drug
design using in silico screening for novel allosteric modulators
will not, in and of itself, guarantee a desired level of selectivity
without complementation by additional structure-function
approaches as described herein.
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